Enovis Corporation

NYSE:ENOV Stock Report

Market Cap: US$2.5b

Enovis Valuation

Is ENOV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ENOV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$107.20
Fair Value
57.7% undervalued intrinsic discount
10
Number of Analysts

Below Fair Value: ENOV ($45.35) is trading below our estimate of fair value ($107.2)

Significantly Below Fair Value: ENOV is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ENOV?

Key metric: As ENOV is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ENOV. This is calculated by dividing ENOV's market cap by their current revenue.
What is ENOV's PS Ratio?
PS Ratio1.3x
SalesUS$2.00b
Market CapUS$2.50b

Price to Sales Ratio vs Peers

How does ENOV's PS Ratio compare to its peers?

The above table shows the PS ratio for ENOV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.1x
LIVN LivaNova
2.1x4.4%US$2.5b
TNDM Tandem Diabetes Care
2.8x10.0%US$2.4b
NUVA NuVasive
1.7x6.7%US$2.1b
CNMD CONMED
1.7x6.4%US$2.1b
ENOV Enovis
1.3x7.2%US$2.5b

Price-To-Sales vs Peers: ENOV is good value based on its Price-To-Sales Ratio (1.3x) compared to the peer average (2.2x).

Price to Sales Ratio vs Industry

How does ENOV's PS Ratio compare vs other companies in the US Medical Equipment Industry?

50 CompaniesPrice / SalesEstimated GrowthMarket Cap
VREX Varex Imaging
0.7x2.3%US$551.26m
VREX Varex Imaging
0.7x2.3%US$551.26m
INGN Inogen
0.7x4.4%US$227.47m
INGN Inogen
0.7x4.4%US$227.47m
ENOV 1.3xIndustry Avg. 3.4xNo. of Companies50PS03.26.49.612.816+
50 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: ENOV is good value based on its Price-To-Sales Ratio (1.3x) compared to the US Medical Equipment industry average (3.4x).

Price to Sales Ratio vs Fair Ratio

What is ENOV's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ENOV PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.3x
Fair PS Ratio2.4x

Price-To-Sales vs Fair Ratio: ENOV is good value based on its Price-To-Sales Ratio (1.3x) compared to the estimated Fair Price-To-Sales Ratio (2.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ENOV forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$45.35
US$66.00
+45.5%
12.4%US$75.00US$50.00n/a10
Jan ’26US$43.88
US$66.00
+50.4%
12.4%US$75.00US$50.00n/a10
Dec ’25US$48.81
US$66.30
+35.8%
12.2%US$75.00US$50.00n/a10
Nov ’25US$42.43
US$66.50
+56.7%
12.2%US$75.00US$50.00n/a10
Oct ’25US$41.47
US$67.00
+61.6%
12.6%US$75.00US$50.00n/a9
Sep ’25US$46.60
US$68.30
+46.6%
11.8%US$76.00US$50.00n/a10
Aug ’25US$46.54
US$72.10
+54.9%
12.3%US$82.00US$53.00n/a10
Jul ’25US$44.35
US$72.18
+62.8%
11.3%US$82.00US$53.00n/a11
Jun ’25US$50.27
US$74.10
+47.4%
7.7%US$82.00US$64.00n/a10
May ’25US$55.40
US$75.20
+35.7%
6.0%US$82.00US$65.00n/a10
Apr ’25US$61.43
US$75.20
+22.4%
6.0%US$82.00US$65.00n/a10
Mar ’25US$60.38
US$75.20
+24.5%
6.0%US$82.00US$65.00n/a10
Feb ’25US$59.61
US$71.33
+19.7%
5.9%US$75.00US$63.00n/a9
Jan ’25US$56.02
US$69.25
+23.6%
7.9%US$75.00US$60.00US$43.888
Dec ’24US$50.97
US$67.57
+32.6%
8.9%US$75.00US$60.00US$48.817
Nov ’24US$45.03
US$70.00
+55.5%
5.1%US$75.00US$65.00US$42.437
Oct ’24US$52.73
US$69.83
+32.4%
4.6%US$75.00US$65.00US$41.476
Sep ’24US$56.50
US$69.83
+23.6%
4.6%US$75.00US$65.00US$46.606
Aug ’24US$63.73
US$68.17
+7.0%
2.9%US$70.00US$65.00US$46.546
Jul ’24US$64.12
US$67.33
+5.0%
3.1%US$70.00US$65.00US$44.356
Jun ’24US$53.79
US$66.80
+24.2%
2.7%US$70.00US$65.00US$50.275
May ’24US$58.71
US$63.11
+7.5%
5.1%US$67.00US$57.54US$55.405
Apr ’24US$53.49
US$63.00
+17.8%
7.3%US$67.00US$53.00US$61.436
Mar ’24US$57.32
US$63.00
+9.9%
7.3%US$67.00US$53.00US$60.386
Feb ’24US$64.47
US$62.83
-2.5%
8.8%US$68.00US$53.00US$59.616
Jan ’24US$53.52
US$60.29
+12.6%
8.8%US$68.00US$53.00US$56.027
Analyst Price Target
Consensus Narrative from 10 Analysts
US$66.00
Fair Value
31.3% undervalued intrinsic discount
10
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/13 23:01
End of Day Share Price 2025/01/13 00:00
Earnings2024/09/27
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Enovis Corporation is covered by 33 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jeffrey JohnsonBaird
null nullBaird
Robert CornellBarclays